메뉴 건너뛰기




Volumn 31, Issue 9, 2016, Pages 1422-1423

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors—A nationwide case-control study

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

EID: 84985914579     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26734     Document Type: Note
Times cited : (65)

References (7)
  • 1
    • 84878542289 scopus 로고    scopus 로고
    • Exenatide and the treatment of patients with Parkinson's disease
    • Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 2013;123:2730–2736.
    • (2013) J Clin Invest , vol.123 , pp. 2730-2736
    • Aviles-Olmos, I.1    Dickson, J.2    Kefalopoulou, Z.3
  • 2
    • 12244311917 scopus 로고    scopus 로고
    • Overview of incretin hormones
    • Efendic S, Portwood N. Overview of incretin hormones. Horm Metab Res 2004;36:742–750.
    • (2004) Horm Metab Res , vol.36 , pp. 742-750
    • Efendic, S.1    Portwood, N.2
  • 3
    • 79958058102 scopus 로고    scopus 로고
    • External review and validation of the Swedish national inpatient register
    • Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
    • (2011) BMC Public Health , vol.11 , pp. 450
    • Ludvigsson, J.F.1    Andersson, E.2    Ekbom, A.3
  • 4
    • 84881552016 scopus 로고    scopus 로고
    • Long-term coeliac disease influences risk of death in patients with type 1 diabetes
    • Mollazadegan K, Sanders DS, Ludvigsson J, Ludvigsson JF. Long-term coeliac disease influences risk of death in patients with type 1 diabetes. J Intern Med 2013;274:273–280.
    • (2013) J Intern Med , vol.274 , pp. 273-280
    • Mollazadegan, K.1    Sanders, D.S.2    Ludvigsson, J.3    Ludvigsson, J.F.4
  • 5
    • 84931292010 scopus 로고    scopus 로고
    • Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors
    • Matteucci E, Giampietro O. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors. Curr Med Chem 2015;22:1573–1581.
    • (2015) Curr Med Chem , vol.22 , pp. 1573-1581
    • Matteucci, E.1    Giampietro, O.2
  • 6
    • 70350328161 scopus 로고    scopus 로고
    • Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
    • Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600–607.
    • (2009) Trends Pharmacol Sci , vol.30 , pp. 600-607
    • Yazbeck, R.1    Howarth, G.S.2    Abbott, C.A.3
  • 7
    • 0031945149 scopus 로고    scopus 로고
    • The CP-I subunit of adenosine deaminase complexing protein from calf kidney is identical to human, mouse, and rat dipeptidyl peptidase IV
    • Ben-Shooshan I, Parola AH. The CP-I subunit of adenosine deaminase complexing protein from calf kidney is identical to human, mouse, and rat dipeptidyl peptidase IV. Comp Biochem Physiol B Biochem Mol Biol 1998;119:289–292.
    • (1998) Comp Biochem Physiol B Biochem Mol Biol , vol.119 , pp. 289-292
    • Ben-Shooshan, I.1    Parola, A.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.